oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs
Zora Biosciences Oy, Espoo, Finland.
Zora Biosciences Oy, Espoo, Finland.
Zora Biosciences Oy, Espoo, Finland.ORCID iD: 0000-0002-2856-9165
2008 (English)In: Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, E-ISSN 1744-7607, Vol. 4, no 6, p. 665-680Article, review/survey (Refereed) Published
Abstract [en]

BACKGROUND: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs.

METHODS: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism.

RESULTS/CONCLUSION: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.

Place, publisher, year, edition, pages
Informa Healthcare, 2008. Vol. 4, no 6, p. 665-680
Keywords [en]
Cardiovascular disease, drug safety, lipid-lowering drugs, lipidomics, metabolomics, myopathy, pathway analysis, pharmacology, statins, toxicology, translational medicine
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-70918DOI: 10.1517/17425255.4.6.665ISI: 000257299400001PubMedID: 18611110Scopus ID: 2-s2.0-48949117174OAI: oai:DiVA.org:oru-70918DiVA, id: diva2:1345901
Available from: 2019-08-26 Created: 2019-08-26 Last updated: 2019-09-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Oresic, Matej

Search in DiVA

By author/editor
Oresic, Matej
In the same journal
Expert Opinion on Drug Metabolism & Toxicology
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 9 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf